News &amp; Updates

In the first-line treatment of patients with adult-onset Still’s disease (AOSD), biological disease-modifying antirheumatic drug (DMARD) therapy is associated with increased likelihood of achieving sustained, event-free remission in addition to fewer complications compared with conventional synthetic (cs) DMARDs, according to a study from Germany.

Adult-onset Still’s disease outcomes better with frontline biological vs csDMARD therapy

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Sodium-glucose cotransporter-2 (SGLT2) inhibitors help reduce the risk of lung function decline and mortality in a low-risk population of patients with type 2 diabetes (T2D) who have normal or low BMI, as shown in a single-centre retrospective study from Korea.

Even low-risk diabetes patients obtain renal, mortality benefits with SGLT2 inhibitors

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

Asymptomatic individuals with incidentally diagnosed coronary artery stenosis may forego the use of aspirin, with a recent study suggesting that it does not provide any significant benefit for the prevention of composite events and bleeding.

Aspirin offers no protection against cardiac events in asymptomatic coronary stenosis

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

Patients with extensive-stage small cell lung cancer (ES-SCLC) derive real-world clinical benefits from first-line treatment with atezolizumab combined with carboplatin and etoposide (CP/ET), reports a recent study.

First-line atezolizumab plus CP/ET offers survival benefits in ES-SCLC

30 May 2025

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Findings from the phase III ELATIVE^® trial demonstrate that the peroxisome proliferator-activated receptor (PPAR) agonist elafibranor improves fatigue in individuals with primary biliary cholangitis (PBC), with limited correlation with pruritus.

Updated ELATIVE analysis reflects elafibranor advantage for fatigue in PBC patients

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

Growth hormone therapy appears to boost height and growth rate in girls with Turner Syndrome (TS) or growth hormone deficiency (GHD), with pronounced effect seen in the first year of treatment, according to a case-control study.

Growth hormone treatment beneficial to girls with Turner syndrome, growth hormone deficiency

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

Women with opioid use disorder (OUD) treated with buprenorphine during pregnancy had significantly lower rates of adverse maternal and infant outcomes than those who did not receive treatment, according to a study presented at PAS 2025.

Lower chance of adverse maternal-infant outcomes with buprenorphine for OUD

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

In critically ill patients with moderate-to-severe acute respiratory distress syndrome (ARDS), inhaled sedation with sevoflurane may lead to fewer ventilator-free days at day 28 and lower 90-day survival compared with sedation with propofol, according to the results of the phase III SESAR study.

Inhaled sedation with sevoflurane not beneficial in moderate-to-severe ARDS

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

29 May 2025 by

IBP-9414, a live biotherapeutic product (LBP), delivers gastrointestinal (GI) and mortality benefits in very low birth weight (VLBW) infants (BW 500–1,500g) born between 23 and 32 weeks gestational age in the phase III Connection study presented at PAS 2025.

IBP-9414 improves GI outcomes, cuts death rates in VLBW infants

Original New Drug Application Approvals by US FDA (16-30 April 2025)

New drug applications approved by US FDA as of 16-30 April 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 April 2025)